AstraZeneca Pharma India Limited

ASTRAZEN

INE203A01020

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:55 27/06/2024 pm IST			5-day change	1st Jan Change
6,370 ^INR	-0.15%		-0.08%	+15.41%

21/06	AstraZeneca Pharma Fails to Find Buyer for Manufacturing Site in Bangalore, India	MT
01/06	Astrazeneca Pharma India Limited Appoints Shikha Mirchandani Chatrath as Director - Commercial Excellence, BD & Strategy, Effective June 17, 2024	CI

Astrazeneca Pharma India Limited Recommends Dividend for the Financial Year 2023-24

May 27, 2024 at 05:55 pm IST

The Board of Directors of the AstraZeneca Pharma India Limited at its meeting held on May 27, 2024, Recommended Dividend of INR 24 per equity share for the financial year 2023-24. subject to approval of shareholders at the Annual General Meeting of the Company.

Latest news about AstraZeneca Pharma India Limited

AstraZeneca Pharma Fails to Find Buyer for Manufacturing Site in Bangalore, India	21/06	MT
Astrazeneca Pharma India Limited Appoints Shikha Mirchandani Chatrath as Director - Commercial Excellence, BD & Strategy, Effective June 17, 2024	01/06	CI
Astrazeneca Pharma India's Net Profit Rises in Fiscal Q4	28/05	MT
AstraZeneca Pharma India Limited Announces Resignation of Ankush Nandra as Non-Executive Director	27/05	CI
Astrazeneca Pharma India Limited Recommends Dividend for the Financial Year 2023-24	27/05	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	27/05	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the Full Year Ended March 31, 2024	27/05	CI
Astrazeneca Pharma India Limited Provides Update on Olaparib 100mg and 150 mg Tablets	21/05	CI
AstraZeneca Pharma India Limited Approves Appointment of Bhavana Agrawal as Director and Whole Time Director	08/04	CI
AstraZeneca Pharma India Limited Appoints Vinay Sharma as Business Unit Head - Rare Disease, Effective July 1, 2024	25/03	CI
AstraZeneca, Mankind Pharma Tie Up for Exclusive Distribution of Asthma Drug Symbicort in India	11/03	MT
Astrazeneca Pharma India Ltd and Mankind Pharma Partner to Accelerate Access to Asthma Medicine for Patients in India	11/03	CI
Astrazeneca Pharma India Limited Announces Board Changes	20/02	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02	CI
AstraZeneca Pharma India Limited Announces Board Changes	08/02	CI
AstraZeneca Pharma India Limited Announces Directorate Appointments	07/02	CI
AstraZeneca Gets Indian Drug Regulator's Nod to Import Andexanet Alfa Powder for Solution for Infusion	22/01	MT
Astrazeneca Pharma to Launch Breast Cancer Treatment Drug in India in January 2024	21/12	MT
India's Nifty set for muted open after steep drop	21/12	RE
Astrazeneca Pharma India Limited Appoints Hooi-Bien Chuah as Additional Director (Non-Executive)	09/11	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11	CI
AstraZeneca Gets Indian Drug Regulator's Nod to Import Pharmaceutical Formulations for Palivizumab	02/23/02	MT
Astrazeneca Pharma India Limited Receives Permission to Import Pharmaceutical Formulations Of New Drug For Sale Or For Distribution In Form CT-20 From Central Drugs Standard Control Organisation For Palivizumab	30/23/30	CI
AstraZeneca Pharma India Limited Announces Management Changes	29/23/29	CI
Astrazeneca Pharma India Limited Announces Retirement of Rajesh Marwaha as Whole-Time Director	29/23/29	CI

Chart AstraZeneca Pharma India Limited

Duration

Period

More charts

Company Profile

AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Companyâs DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PHARMA INDIA LIMITED	+15.41%	1.91B
ELI LILLY AND COMPANY	+54.61%	811B
NOVO NORDISK A/S	+43.68%	640B
JOHNSON & JOHNSON	-6.33%	353B
MERCK & CO., INC.	+20.62%	333B
ABBVIE INC.	+10.44%	302B
ASTRAZENECA PLC	+17.62%	246B
ROCHE HOLDING AG	+2.58%	225B
NOVARTIS AG	+12.57%	218B
AMGEN INC.	+8.61%	168B